Osang Healthcare
132 Anyangcheon-dong-ro, Dongan-gu, Anyang-si, Gyeonggi-do, 14042, South Korea
Overview
Devoted since inception to the development of diagnostic biosensors for blood glucose measurement, OSANG Healthcare envisions medical devices becoming as commonplace as home appliances, easily measuring all diseases across the globe as “Technology for Human.” Today, we export the world’s best diagnostic biosensors for blood glucose, HbA1c, and cholesterol to more than 110 countries the world over, in our drive to become the leading researcher and developer of diagnostic sensors for heart disease and cancer, and of remote diagnosis systems.
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Health Care
- Health Diagnostics
- Medical Device
Investment portfolio
- Allez Health
Led · Series A · May 2024
Allez Health develops an investigational continuous glucose monitoring (CGM) biosensor platform that aims to lower cost while improving performance and user experience. The company reports seven issued patents and over 40 pending patent applications. It has run more than 80 clinical studies aggregating over 1,500 users and completed a pivotal study in 120 insulin users. Allez Health plans to use new capital to support regulatory approval filings and to scale manufacturing and distribution arrangements. The sensor remains an investigational device and is not yet cleared or approved by the U.S. FDA or other regulatory authorities. Leadership emphasizes bringing an affordable, reliable CGM sensor to market for diabetes and broader wellness users.
- Kryptos Biotechnologies
Led · Series A · Apr 2024
Kryptos Biotechnologies develops photothermal heating technology that uses light to generate heat and control temperature for molecular diagnostic devices and life‑science instruments. Its PCR‑based point‑of‑care system delivers a sample‑to‑answer in about 20 minutes while aiming to match lab accuracy. The company intends to use the Series A proceeds to advance clinical studies of respiratory combo tests and pursue FDA approval by 2025. Kryptos has entered a strategic partnership with Osang Healthcare for manufacturing and distribution of its product. The company is led by CEO Jinyong Lee and is based in Hayward, California. It raised $10M in the reported financing to support clinical and regulatory milestones.
Team
Chulhun Kang
CEO